Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Eli Lilly completes acquisition of Prevail Therapeutics » 08:56
01/22/21
01/22
08:56
01/22/21
08:56
LLY

Eli Lilly

$202.26 /

+0.915 (+0.45%)

, PRVL

Prevail Therapeutics

$22.97 /

-0.08 (-0.35%)

Eli Lilly and Company…

Eli Lilly and Company (LLY) announced the successful completion of its acquisition of Prevail Therapeutics (PRVL). The acquisition establishes a new modality for drug discovery and development at Lilly, extending Lilly's research efforts through the creation of a gene therapy program that will be anchored by Prevail's portfolio of clinical-stage and preclinical neuroscience assets. The impact of this transaction will be reflected in Lilly's 2021 financial results according to Generally Accepted Accounting Principles. There will be no change to Lilly's 2021 financial guidance for research and development expense or non-GAAP earnings per share as a result of this transaction.

ShowHide Related Items >><<
PRVL Prevail Therapeutics
$22.97 /

-0.08 (-0.35%)

LLY Eli Lilly
$202.26 /

+0.915 (+0.45%)

LLY Eli Lilly
$202.26 /

+0.915 (+0.45%)

01/20/21 Citi
Citi opens 'positive Catalyst Watch' on Eli Lilly into Alzheimer's data
01/19/21 Roth Capital
Merus price target raised to $32 from $19 at Roth Capital
01/19/21
Fly Intel: Top five analyst upgrades
01/19/21 Mizuho
Eli Lilly upgraded to Buy from Neutral at Mizuho
PRVL Prevail Therapeutics
$22.97 /

-0.08 (-0.35%)

12/23/20 Wedbush
Prevail Therapeutics downgraded to Neutral from Outperform at Wedbush
12/16/20 Stifel
Prevail Therapeutics downgraded to Hold from Buy at Stifel
12/16/20 Citi
Prevail Therapeutics downgraded to Neutral from Buy at Citi
12/15/20 Cowen
Prevail Therapeutics downgraded to Market Perform from Outperform at Cowen
PRVL Prevail Therapeutics
$22.97 /

-0.08 (-0.35%)

LLY Eli Lilly
$202.26 /

+0.915 (+0.45%)

LLY Eli Lilly
$202.26 /

+0.915 (+0.45%)

PRVL Prevail Therapeutics
$22.97 /

-0.08 (-0.35%)

LLY Eli Lilly
$202.26 /

+0.915 (+0.45%)

LLY Eli Lilly
$202.26 /

+0.915 (+0.45%)

Hot Stocks
Humanigen announces expansion of CRADA for lenzilumab development » 07:03
01/22/21
01/22
07:03
01/22/21
07:03
HGEN

Humanigen

$18.81 /

-0.13 (-0.69%)

Humanigen announced an…

Humanigen announced an expansion to the Cooperative Research and Development Agreement, or CRADA, that the company had previously entered into with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, or JPEO-CBRND, to gain access to manufacturing capacity reserved by the Biomedical Advanced Research and Development Authority, or BARDA, part of the Office of the Assistant Secretary for Preparedness and Response, or ASPR, at the U.S. Department of Health and Human Services. The agreement supports development of lenzilumab in advance of a potential Emergency Use Authorization, or EUA, for COVID-19. The amended CRADA, now co-signed by BARDA, provides Humanigen with access to manufacturing capacity reserved by BARDA for fill-finish product to accelerate the drug product manufacturing of lenzilumab. The initial agreement, originally signed in November 2020, complements Humanigen's development efforts for lenzilumab by providing access to a full-scale, integrated team of manufacturing and regulatory subject matter experts and statistical support in anticipation of applying for EUA and subsequently a biologics license application, or BLA, for lenzilumab as a potential treatment for COVID-19. Lenzilumab is currently in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19.

ShowHide Related Items >><<
HGEN Humanigen
$18.81 /

-0.13 (-0.69%)

HGEN Humanigen
$18.81 /

-0.13 (-0.69%)

01/20/21 Jefferies
Jefferies reads Humanigen COVID-19 trial change as 'sign of confidence'
12/23/20 National Securities
Humanigen initiated with a Buy at National Securities
12/22/20
Fly Intel: Top five analyst initiations
12/22/20 Jefferies
Humanigen initiated with a Buy at Jefferies
HGEN Humanigen
$18.81 /

-0.13 (-0.69%)

  • 18
    Sep
HGEN Humanigen
$18.81 /

-0.13 (-0.69%)

HGEN Humanigen
$18.81 /

-0.13 (-0.69%)

Thursday
On The Fly
Fly Intel: Wall Street's top stories for Thursday » 16:40
01/21/21
01/21
16:40
01/21/21
16:40
UAL

United Airlines

$42.59 /

-2.59 (-5.73%)

, TRV

Travelers

$148.81 /

+3.73 (+2.57%)

, LLY

Eli Lilly

$202.26 /

+0.915 (+0.45%)

, ABCL

AbCellera

$50.91 /

+2.68 (+5.56%)

, CTVA

Corteva

$41.65 /

-2.02 (-4.63%)

, CLGX

CoreLogic

$76.78 /

+1.07 (+1.41%)

, CSGP

CoStar Group

$913.01 /

+12.01 (+1.33%)

, DBD

Diebold

$13.05 /

+1.85 (+16.52%)

, TAL

TAL Education

$78.02 /

+10.29 (+15.19%)

, UAA

Under Armour

$18.69 /

+0.08 (+0.43%)

, UA

Under Armour

$16.11 /

+0.135 (+0.85%)

, DYN

Dyne Therapeutics

$21.24 /

-7.65 (-26.48%)

, INMB

INmune Bio

$20.45 /

-4.64 (-18.49%)

Stocks on Wall Street…

ShowHide Related Items >><<
UAL United Airlines
$42.59 /

-2.59 (-5.73%)

UAA Under Armour
$18.69 /

+0.08 (+0.43%)

TRV Travelers
$148.81 /

+3.73 (+2.57%)

TAL TAL Education
$78.02 /

+10.29 (+15.19%)

LLY Eli Lilly
$202.26 /

+0.915 (+0.45%)

INMB INmune Bio
$20.45 /

-4.64 (-18.49%)

DYN Dyne Therapeutics
$21.24 /

-7.65 (-26.48%)

DBD Diebold
$13.05 /

+1.85 (+16.52%)

CTVA Corteva
$41.65 /

-2.02 (-4.63%)

CSGP CoStar Group
$913.01 /

+12.01 (+1.33%)

CLGX CoreLogic
$76.78 /

+1.07 (+1.41%)

ABCL AbCellera
$50.91 /

+2.68 (+5.56%)

UAL United Airlines
$42.59 /

-2.59 (-5.73%)

01/14/21 Susquehanna
United Airlines price target raised to $40 from $38 at Susquehanna
01/11/21 Cowen
United Airlines upgraded to Outperform from Market Perform at Cowen
01/08/21
Fly Intel: Top five analyst downgrades
01/08/21 BofA
United Airlines downgraded to Underperform from Neutral at BofA
TRV Travelers
$148.81 /

+3.73 (+2.57%)

01/22/21 RBC Capital
Travelers price target raised to $156 from $122 at RBC Capital
01/22/21 Barclays
Travelers price target raised to $155 from $150 at Barclays
01/04/21 JPMorgan
Travelers price target raised to $136 from $129 at JPMorgan
11/27/20 MKM Partners
Travelers price target raised to $160 from $140 at MKM Partners
LLY Eli Lilly
$202.26 /

+0.915 (+0.45%)

01/20/21 Citi
Citi opens 'positive Catalyst Watch' on Eli Lilly into Alzheimer's data
01/19/21 Roth Capital
Merus price target raised to $32 from $19 at Roth Capital
01/19/21
Fly Intel: Top five analyst upgrades
01/19/21 Mizuho
Eli Lilly upgraded to Buy from Neutral at Mizuho
ABCL AbCellera
$50.91 /

+2.68 (+5.56%)

01/05/21
Fly Intel: Top five analyst initiations
01/05/21 SVB Leerink
SVB Leerink bullish on AbCellera, initiates with an Outperform
01/05/21 Berenberg
AbCellera initiated with a Buy at Berenberg
01/05/21 Credit Suisse
AbCellera initiated with an Outperform at Credit Suisse
CTVA Corteva
$41.65 /

-2.02 (-4.63%)

01/21/21 Redburn
Corteva downgraded to Neutral from Buy at Redburn
01/19/21 Deutsche Bank
Corteva named 'Catalyst Call: Buy Idea' at Deutsche Bank
01/08/21 Deutsche Bank
Corteva price target raised to $50 from $40 at Deutsche Bank
12/18/20 Susquehanna
Corteva downgraded to Neutral from Positive at Susquehanna
CLGX CoreLogic
$76.78 /

+1.07 (+1.41%)

01/06/21 Wolfe Research
CoreLogic downgraded to Underperform from Peer Perform at Wolfe Research
12/01/20 Truist
CoreLogic downgraded to Hold from Buy at Truist
12/01/20 Truist
CoreLogic downgraded to Hold from Buy at Truist
10/28/20 Truist
CoreLogic could be sold for 'meaningfully more' than $80 per share, says Truist
CSGP CoStar Group
$913.01 /

+12.01 (+1.33%)

12/22/20 JMP Securities
RealPage price target raised to $101 from $80 at JMP Securities
11/23/20 Wells Fargo
CoStar Group price target raised to $990 from $915 at Wells Fargo
10/28/20 Needham
CoStar Group price target raised to $1,000 from $825 at Needham
DBD Diebold
$13.05 /

+1.85 (+16.52%)

01/21/21 JPMorgan
JPMorgan upgrades 'deep value stock' Diebold to Overweight
01/21/21 JPMorgan
Diebold upgraded to Overweight from Neutral at JPMorgan
10/27/20 JPMorgan
Diebold assumed with a Neutral at JPMorgan
10/27/20 JPMorgan
NCR Corp. upgraded to Overweight from Neutral at JPMorgan
TAL TAL Education
$78.02 /

+10.29 (+15.19%)

01/22/21 UBS
TAL Education price target raised to $108 from $99 at UBS
01/22/21 CICC
TAL Education upgraded to Outperform from Market Perform at CICC
01/22/21 Credit Suisse
TAL Education downgraded to Neutral from Outperform at Credit Suisse
12/30/20 Credit Suisse
Credit Suisse cuts TAL target to $79 on margin pressure from online competition
UAA Under Armour
$18.69 /

+0.08 (+0.43%)

01/21/21 Deutsche Bank
Under Armour upgraded to Buy from Hold at Deutsche Bank
01/21/21 Deutsche Bank
Under Armour upgraded to Buy from Hold at Deutsche Bank
01/15/21 B. Riley Securities
Under Armour price target raised to $15 from $13 at B. Riley Securities
01/07/21 JPMorgan
Under Armour price target raised to $19 from $17 at JPMorgan
UA Under Armour
$16.11 /

+0.135 (+0.85%)

01/04/21 Pivotal Research
Under Armour upgraded to Buy from Hold at Pivotal Research
DYN Dyne Therapeutics
$21.24 /

-7.65 (-26.48%)

01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
10/12/20 JPMorgan
Dyne Therapeutics initiated with an Overweight at JPMorgan
10/12/20 Stifel
Dyne Therapeutics initiated with a Buy at Stifel
INMB INmune Bio
$20.45 /

-4.64 (-18.49%)

01/22/21 Maxim
INmune Bio price target raised to $32 from $16 at Maxim
09/01/20 BTIG
INmune Bio initiated with a Buy at BTIG
07/14/20 Roth Capital
INmune Bio price target raised to $26 from $13 at Roth Capital
03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
UAL United Airlines
$42.59 /

-2.59 (-5.73%)

UAA Under Armour
$18.69 /

+0.08 (+0.43%)

TRV Travelers
$148.81 /

+3.73 (+2.57%)

TAL TAL Education
$78.02 /

+10.29 (+15.19%)

LLY Eli Lilly
$202.26 /

+0.915 (+0.45%)

INMB INmune Bio
$20.45 /

-4.64 (-18.49%)

DYN Dyne Therapeutics
$21.24 /

-7.65 (-26.48%)

DBD Diebold
$13.05 /

+1.85 (+16.52%)

CTVA Corteva
$41.65 /

-2.02 (-4.63%)

CSGP CoStar Group
$913.01 /

+12.01 (+1.33%)

CLGX CoreLogic
$76.78 /

+1.07 (+1.41%)

  • 21
    Jan
  • 11
    Dec
  • 17
    Sep
  • 16
    Jul
  • 21
    May
  • 22
    Apr
UAL United Airlines
$42.59 /

-2.59 (-5.73%)

UAA Under Armour
$18.69 /

+0.08 (+0.43%)

TRV Travelers
$148.81 /

+3.73 (+2.57%)

TAL TAL Education
$78.02 /

+10.29 (+15.19%)

LLY Eli Lilly
$202.26 /

+0.915 (+0.45%)

CTVA Corteva
$41.65 /

-2.02 (-4.63%)

CSGP CoStar Group
$913.01 /

+12.01 (+1.33%)

CLGX CoreLogic
$76.78 /

+1.07 (+1.41%)

UAL United Airlines
$42.59 /

-2.59 (-5.73%)

UAA Under Armour
$18.69 /

+0.08 (+0.43%)

TRV Travelers
$148.81 /

+3.73 (+2.57%)

LLY Eli Lilly
$202.26 /

+0.915 (+0.45%)

DYN Dyne Therapeutics
$21.24 /

-7.65 (-26.48%)

CLGX CoreLogic
$76.78 /

+1.07 (+1.41%)

ABCL AbCellera
$50.91 /

+2.68 (+5.56%)

UAL United Airlines
$42.59 /

-2.59 (-5.73%)

UAA Under Armour
$18.69 /

+0.08 (+0.43%)

UA Under Armour
$16.11 /

+0.135 (+0.85%)

TRV Travelers
$148.81 /

+3.73 (+2.57%)

TAL TAL Education
$78.02 /

+10.29 (+15.19%)

LLY Eli Lilly
$202.26 /

+0.915 (+0.45%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:14
01/21/21
01/21
12:14
01/21/21
12:14
DBD

Diebold

$12.66 /

+1.46 (+13.04%)

, UAL

United Airlines

$42.11 /

-3.07 (-6.80%)

, TRV

Travelers

$148.16 /

+3.08 (+2.12%)

, LLY

Eli Lilly

$198.27 /

-3.075 (-1.53%)

, ABCL

AbCellera

$48.96 /

+0.73 (+1.51%)

, UAA

Under Armour

$18.83 /

+0.22 (+1.18%)

, UA

Under Armour

$16.18 /

+0.205 (+1.28%)

, TAL

TAL Education

$78.33 /

+10.6 (+15.65%)

, DYN

Dyne Therapeutics

$22.60 /

-6.29 (-21.77%)

, INMB

INmune Bio

$21.02 /

-4.07 (-16.22%)

The major averages are…

ShowHide Related Items >><<
UAL United Airlines
$42.11 /

-3.07 (-6.80%)

UAA Under Armour
$18.83 /

+0.22 (+1.18%)

TRV Travelers
$148.16 /

+3.08 (+2.12%)

TAL TAL Education
$78.33 /

+10.6 (+15.65%)

LLY Eli Lilly
$198.27 /

-3.075 (-1.53%)

INMB INmune Bio
$21.02 /

-4.07 (-16.22%)

DYN Dyne Therapeutics
$22.60 /

-6.29 (-21.77%)

DBD Diebold
$12.66 /

+1.46 (+13.04%)

ABCL AbCellera
$48.96 /

+0.73 (+1.51%)

DBD Diebold
$12.66 /

+1.46 (+13.04%)

01/21/21 JPMorgan
JPMorgan upgrades 'deep value stock' Diebold to Overweight
01/21/21 JPMorgan
Diebold upgraded to Overweight from Neutral at JPMorgan
10/27/20 JPMorgan
Diebold assumed with a Neutral at JPMorgan
10/27/20 JPMorgan
NCR Corp. upgraded to Overweight from Neutral at JPMorgan
UAL United Airlines
$42.11 /

-3.07 (-6.80%)

01/14/21 Susquehanna
United Airlines price target raised to $40 from $38 at Susquehanna
01/11/21 Cowen
United Airlines upgraded to Outperform from Market Perform at Cowen
01/08/21
Fly Intel: Top five analyst downgrades
01/08/21 BofA
United Airlines downgraded to Underperform from Neutral at BofA
TRV Travelers
$148.16 /

+3.08 (+2.12%)

01/04/21 JPMorgan
Travelers price target raised to $136 from $129 at JPMorgan
11/27/20 MKM Partners
Travelers price target raised to $160 from $140 at MKM Partners
11/17/20 Barclays
Travelers initiated with an Overweight at Barclays
10/29/20 BofA
Chubb upgraded to Neutral at BofA with valuation gap to Travelers narrowed
LLY Eli Lilly
$198.27 /

-3.075 (-1.53%)

01/20/21 Citi
Citi opens 'positive Catalyst Watch' on Eli Lilly into Alzheimer's data
01/19/21 Roth Capital
Merus price target raised to $32 from $19 at Roth Capital
01/19/21
Fly Intel: Top five analyst upgrades
01/19/21 Mizuho
Eli Lilly upgraded to Buy from Neutral at Mizuho
ABCL AbCellera
$48.96 /

+0.73 (+1.51%)

01/05/21
Fly Intel: Top five analyst initiations
01/05/21 SVB Leerink
SVB Leerink bullish on AbCellera, initiates with an Outperform
01/05/21 Berenberg
AbCellera initiated with a Buy at Berenberg
01/05/21 Credit Suisse
AbCellera initiated with an Outperform at Credit Suisse
UAA Under Armour
$18.83 /

+0.22 (+1.18%)

01/21/21 Deutsche Bank
Under Armour upgraded to Buy from Hold at Deutsche Bank
01/21/21 Deutsche Bank
Under Armour upgraded to Buy from Hold at Deutsche Bank
01/15/21 B. Riley Securities
Under Armour price target raised to $15 from $13 at B. Riley Securities
01/07/21 JPMorgan
Under Armour price target raised to $19 from $17 at JPMorgan
UA Under Armour
$16.18 /

+0.205 (+1.28%)

01/04/21 Pivotal Research
Under Armour upgraded to Buy from Hold at Pivotal Research
TAL TAL Education
$78.33 /

+10.6 (+15.65%)

12/30/20 Credit Suisse
Credit Suisse cuts TAL target to $79 on margin pressure from online competition
12/29/20 CLSA
TAL Education now has 'war chest' to fight competition, says CLSA
11/25/20 Morgan Stanley
OneSmart downgraded to Equal Weight on margin pressure at Morgan Stanley
10/26/20 JPMorgan
TAL Education downgraded to Neutral from Overweight at JPMorgan (Friday)
DYN Dyne Therapeutics
$22.60 /

-6.29 (-21.77%)

01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
10/12/20 JPMorgan
Dyne Therapeutics initiated with an Overweight at JPMorgan
10/12/20 Stifel
Dyne Therapeutics initiated with a Buy at Stifel
INMB INmune Bio
$21.02 /

-4.07 (-16.22%)

09/01/20 BTIG
INmune Bio initiated with a Buy at BTIG
07/14/20 Roth Capital
INmune Bio price target raised to $26 from $13 at Roth Capital
03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
UAL United Airlines
$42.11 /

-3.07 (-6.80%)

UAA Under Armour
$18.83 /

+0.22 (+1.18%)

TRV Travelers
$148.16 /

+3.08 (+2.12%)

TAL TAL Education
$78.33 /

+10.6 (+15.65%)

LLY Eli Lilly
$198.27 /

-3.075 (-1.53%)

INMB INmune Bio
$21.02 /

-4.07 (-16.22%)

DYN Dyne Therapeutics
$22.60 /

-6.29 (-21.77%)

DBD Diebold
$12.66 /

+1.46 (+13.04%)

  • 21
    Jan
  • 11
    Dec
  • 17
    Sep
  • 16
    Jul
  • 22
    Apr
UAL United Airlines
$42.11 /

-3.07 (-6.80%)

UAA Under Armour
$18.83 /

+0.22 (+1.18%)

TRV Travelers
$148.16 /

+3.08 (+2.12%)

TAL TAL Education
$78.33 /

+10.6 (+15.65%)

LLY Eli Lilly
$198.27 /

-3.075 (-1.53%)

UAL United Airlines
$42.11 /

-3.07 (-6.80%)

UAA Under Armour
$18.83 /

+0.22 (+1.18%)

TRV Travelers
$148.16 /

+3.08 (+2.12%)

LLY Eli Lilly
$198.27 /

-3.075 (-1.53%)

DYN Dyne Therapeutics
$22.60 /

-6.29 (-21.77%)

ABCL AbCellera
$48.96 /

+0.73 (+1.51%)

UAL United Airlines
$42.11 /

-3.07 (-6.80%)

UAA Under Armour
$18.83 /

+0.22 (+1.18%)

UA Under Armour
$16.18 /

+0.205 (+1.28%)

TRV Travelers
$148.16 /

+3.08 (+2.12%)

TAL TAL Education
$78.33 /

+10.6 (+15.65%)

LLY Eli Lilly
$198.27 /

-3.075 (-1.53%)

Hot Stocks
AbCellera-discovered antibody prevented COVID-19 in nursing homes, reduced risks » 08:31
01/21/21
01/21
08:31
01/21/21
08:31
ABCL

AbCellera

$48.23 /

-0.91 (-1.85%)

, LLY

Eli Lilly

$201.28 /

+2.755 (+1.39%)

AbCellera (ABCL)…

AbCellera (ABCL) announced that bamlanivimab, LY-CoV555, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (LLY) , significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. Lilly's Phase 3 BLAZE-2 COVID-19 prevention trial was conducted in partnership with the National Institute of Allergy and Infectious Diseases, NIAID, part of the National Institutes of Health , NIH, and the COVID-19 Prevention Network, CoVPN. bamlanivimab. "The data from the Phase 3 BLAZE-2 trial show that bamlanivimab provides effective protection against COVID-19 infection, with the greatest impact on the most vulnerable patients," said Carl Hansen, Ph.D., CEO and President of AbCellera. "Furthermore, data obtained from the treatment group are completely consistent with what was observed in the BLAZE-1 trial. This reinforces the importance of efforts to ensure high-risk patients get access to antibody therapy early in COVID-19 infection. We believe bamlanivimab can save lives if delivered early."

ShowHide Related Items >><<
LLY Eli Lilly
$201.28 /

+2.755 (+1.39%)

ABCL AbCellera
$48.23 /

-0.91 (-1.85%)

ABCL AbCellera
$48.23 /

-0.91 (-1.85%)

01/05/21
Fly Intel: Top five analyst initiations
01/05/21 SVB Leerink
SVB Leerink bullish on AbCellera, initiates with an Outperform
01/05/21 Berenberg
AbCellera initiated with a Buy at Berenberg
01/05/21 Credit Suisse
AbCellera initiated with an Outperform at Credit Suisse
LLY Eli Lilly
$201.28 /

+2.755 (+1.39%)

01/20/21 Citi
Citi opens 'positive Catalyst Watch' on Eli Lilly into Alzheimer's data
01/19/21 Roth Capital
Merus price target raised to $32 from $19 at Roth Capital
01/19/21
Fly Intel: Top five analyst upgrades
01/19/21 Mizuho
Eli Lilly upgraded to Buy from Neutral at Mizuho
LLY Eli Lilly
$201.28 /

+2.755 (+1.39%)

  • 11
    Dec
LLY Eli Lilly
$201.28 /

+2.755 (+1.39%)

LLY Eli Lilly
$201.28 /

+2.755 (+1.39%)

ABCL AbCellera
$48.23 /

-0.91 (-1.85%)

LLY Eli Lilly
$201.28 /

+2.755 (+1.39%)

Hot Stocks
Eli Lilly: LY-CoV555 prevented Covid-19 at nursing homes in Blaze-2 trial » 08:05
01/21/21
01/21
08:05
01/21/21
08:05
LLY

Eli Lilly

$201.28 /

+2.755 (+1.39%)

Bamlanivimab, or…

Bamlanivimab, or LY-CoV555, significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company announced. The Phase 3 BLAZE-2 COVID-19 prevention trial - conducted in partnership with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health and the COVID-19 Prevention Network - enrolled residents and staff at skilled nursing and assisted living facilities, commonly referred to as nursing homes, across the U.S. The 965 participants who tested negative for the SARS-CoV-2 virus at baseline were included in the analysis of primary and key secondary endpoints for assessing prevention, while the 132 participants who tested positive for the virus at baseline were included in exploratory analyses for assessing treatment, adding to the growing body of evidence for treatment with bamlanivimab. All participants were randomized to receive either 4,200 mg of bamlanivimab or placebo. After all participants reached 8 weeks of follow-up, there was a significantly lower frequency of symptomatic COVID-19 in the bamlanivimab treatment arm versus placebo. Results for all key secondary endpoints also reached statistical significance in both the overall and resident populations. Among the 299 residents in the prevention group, there were 4 deaths attributed to COVID-19 at the time of death, and all occurred in the placebo arm. There were no COVID-19 attributed deaths in the bamlanivimab arm. Among the 41 residents in the treatment group, there were 4 deaths, and all occurred in the placebo arm with none in the bamlanivimab arm. Over the entire trial, there were a total of 16 deaths reported, including deaths not related to COVID-19, and all deaths were residents.

ShowHide Related Items >><<
LLY Eli Lilly
$201.28 /

+2.755 (+1.39%)

LLY Eli Lilly
$201.28 /

+2.755 (+1.39%)

01/20/21 Citi
Citi opens 'positive Catalyst Watch' on Eli Lilly into Alzheimer's data
01/19/21 Roth Capital
Merus price target raised to $32 from $19 at Roth Capital
01/19/21
Fly Intel: Top five analyst upgrades
01/19/21 Mizuho
Eli Lilly upgraded to Buy from Neutral at Mizuho
LLY Eli Lilly
$201.28 /

+2.755 (+1.39%)

LLY Eli Lilly
$201.28 /

+2.755 (+1.39%)

LLY Eli Lilly
$201.28 /

+2.755 (+1.39%)

LLY Eli Lilly
$201.28 /

+2.755 (+1.39%)

Wednesday
Recommendations
Jefferies reads Humanigen COVID-19 trial change as 'sign of confidence' » 09:28
01/20/21
01/20
09:28
01/20/21
09:28
HGEN

Humanigen

$20.65 /

+2.46 (+13.52%)

After Humanigen disclosed…

After Humanigen disclosed that the company has changed the primary endpoint of its ongoing Phase 3 clinical trial of lenzilumab in hospitalized patients with COVID-19 to ventilator-free survival through day 28, previously one of several secondary endpoints, Jefferies analyst Kelly Shi said that switching to the "more challenging" primary endpoint is "a positive sign for trial outcome" and a "sign of confidence." The analyst, who thinks lenzilumab will be viewed "as a game changer if the trial succeeds," would use the "panic selling post-market" as a buying opportunity. Shi keeps a Buy rating and $27 price target on Humanigen shares.

ShowHide Related Items >><<
HGEN Humanigen
$20.65 /

+2.46 (+13.52%)

HGEN Humanigen
$20.65 /

+2.46 (+13.52%)

12/23/20 National Securities
Humanigen initiated with a Buy at National Securities
12/22/20
Fly Intel: Top five analyst initiations
12/22/20 Jefferies
Humanigen initiated with a Buy at Jefferies
11/06/20 H.C. Wainwright
Humanigen price target raised to $34 from $31 at H.C. Wainwright
HGEN Humanigen
$20.65 /

+2.46 (+13.52%)

  • 18
    Sep
HGEN Humanigen
$20.65 /

+2.46 (+13.52%)

HGEN Humanigen
$20.65 /

+2.46 (+13.52%)

Hot Stocks
Humanigen changes primary endpoint of lenzilumab trial in COVID-19 patients » 09:24
01/20/21
01/20
09:24
01/20/21
09:24
HGEN

Humanigen

$20.65 /

+2.46 (+13.52%)

In a regulatory filing…

In a regulatory filing last night, Humanigen noted that the company provided an update on its ongoing Phase 3 clinical trial of lenzilumab in hospitalized patients with COVID-19. "As of January 19, 2021, more than 500 patients have been enrolled in the trial. In response to the rapidly evolving therapeutic landscape, the primary endpoint of the trial has been changed to ventilator-free survival through day 28, previously one of several secondary endpoints. Time to recovery will be one of several secondary endpoints. The company believes this change in the primary endpoint represents a more meaningful endpoint for patients, health-care providers, and payors given the current standard of care for hospitalized and hypoxic COVID-19 patients. The protocol and statistical analysis plan for the Phase 3 trial have been updated to reflect these changes. These changes have been reviewed and discussed with FDA and are expected to be posted to clinicaltrials.gov (NCT04351152). The company remains blinded to the results of this ongoing trial," Humanigen said.

ShowHide Related Items >><<
HGEN Humanigen
$20.65 /

+2.46 (+13.52%)

HGEN Humanigen
$20.65 /

+2.46 (+13.52%)

12/23/20 National Securities
Humanigen initiated with a Buy at National Securities
12/22/20
Fly Intel: Top five analyst initiations
12/22/20 Jefferies
Humanigen initiated with a Buy at Jefferies
11/06/20 H.C. Wainwright
Humanigen price target raised to $34 from $31 at H.C. Wainwright
HGEN Humanigen
$20.65 /

+2.46 (+13.52%)

  • 18
    Sep
HGEN Humanigen
$20.65 /

+2.46 (+13.52%)

HGEN Humanigen
$20.65 /

+2.46 (+13.52%)

Recommendations
Citi opens 'positive Catalyst Watch' on Eli Lilly into Alzheimer's data » 06:37
01/20/21
01/20
06:37
01/20/21
06:37
LLY

Eli Lilly

/

+

Citi analyst Andrew Baum…

Citi analyst Andrew Baum opens a opening a "positive Catalyst Watch" on Eli Lilly ahead of presentation of donanemab data at March 13 conference. The analyst keeps a Neutral rating on the shares with a $210 price target. While market expectations have "materially increased" following Lilly's top-line data release earlier this month, Lilly will showcase clinically significant slowing on both cognition and function across subgroups, Baum tells investors in a research note.

ShowHide Related Items >><<
LLY Eli Lilly
/

+

LLY Eli Lilly
/

+

01/19/21 Roth Capital
Merus price target raised to $32 from $19 at Roth Capital
01/19/21
Fly Intel: Top five analyst upgrades
01/19/21 Mizuho
Eli Lilly upgraded to Buy from Neutral at Mizuho
01/12/21 Truist
Eli Lilly price target raised to $200 from $182 at Truist
LLY Eli Lilly
/

+

LLY Eli Lilly
/

+

LLY Eli Lilly
/

+

LLY Eli Lilly
/

+

Tuesday
Recommendations
Merus price target raised to $32 from $19 at Roth Capital » 10:50
01/19/21
01/19
10:50
01/19/21
10:50
MRUS

Merus

$23.61 /

+0.29 (+1.24%)

, LLY

Eli Lilly

$195.53 /

+4.68 (+2.45%)

Roth Capital analyst Tony…

Roth Capital analyst Tony Butler raised the firm's price target on Merus (MRUS) to $32 from $19 and keeps a Buy rating on the shares after the company announced a research collaboration with Eli Lilly (LLY) to develop up to three CD3-engaging bispecific antibodies. Merus is getting $60M in total upfront payment as well as potential milestone payments and royalties. CD3-engaging biologics have been successful in treating hematologic malignancies, Butler tells investors in a research note.

ShowHide Related Items >><<
MRUS Merus
$23.61 /

+0.29 (+1.24%)

LLY Eli Lilly
$195.53 /

+4.68 (+2.45%)

MRUS Merus
$23.61 /

+0.29 (+1.24%)

09/02/20 Roth Capital
Roth Capital keeps Buy on Merus after delay of cancer data
06/26/20 H.C. Wainwright
Merus initiated with a Buy at H.C. Wainwright
05/27/20
Fly Intel: Top five analyst downgrades
05/27/20 RBC Capital
Merus downgraded to Sector Perform from Outperform at RBC Capital
LLY Eli Lilly
$195.53 /

+4.68 (+2.45%)

01/19/21
Fly Intel: Top five analyst upgrades
01/19/21 Mizuho
Eli Lilly upgraded to Buy from Neutral at Mizuho
01/12/21 Truist
Eli Lilly price target raised to $200 from $182 at Truist
01/11/21 JPMorgan
Alzheimer's data a 'significant positive' for Eli Lilly story, says JPMorgan
MRUS Merus
$23.61 /

+0.29 (+1.24%)

LLY Eli Lilly
$195.53 /

+4.68 (+2.45%)

LLY Eli Lilly
$195.53 /

+4.68 (+2.45%)

MRUS Merus
$23.61 /

+0.29 (+1.24%)

LLY Eli Lilly
$195.53 /

+4.68 (+2.45%)

LLY Eli Lilly
$195.53 /

+4.68 (+2.45%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.